Kura Oncology Inc buy melinda
Startpreis
06.11.18
/
50%
10,64 €
Kursziel
10.12.18
14,34 €
Rendite (%)
16,15 %
Endpreis
10.12.18
12,36 €
Zusammenfassung
Diese Einschätzung wurde am 10.12.18 mit einem Endkurs von 12,36 € beendet. Die Einschätzung konnte insgesamt eine Rendite von 16,15 % verzeichnen. melinda hat 50% Zuversicht bei dieser Einschätzung
Finanztrends
Rendite ohne Dividenden (%)
Name | 1W | 1M | 1J | 3J |
---|---|---|---|---|
Kura Oncology Inc | 4,58 % | 4,58 % | 106,98 % | 18,46 % |
iShares Core DAX® | -0,37 % | 5,24 % | 16,91 % | 16,02 % |
iShares Nasdaq 100 | -1,95 % | 1,68 % | 19,89 % | 31,83 % |
iShares Nikkei 225® | -1,69 % | 7,29 % | 12,20 % | 3,40 % |
iShares S&P 500 | -0,40 % | 2,38 % | 20,97 % | 36,22 % |
Kommentare von melinda zu dieser Einschätzung
In der Diskussion Kura Oncology Inc diskutieren
SecteurRecherche biotechnologique et médicale Agenda 05/11 Publication de résultats
Provides biopharmaceutical services
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer.
Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias.
The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer.
Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias.
The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.
Nombre d'employés : 31 personnes.
(Vom Mitglied beendet)
Beendete Einschätzungen von melinda zu Kura Oncology Inc
Kura Oncology Inc
Startkurs
Kursziel
Rendite (%)
15,33 €
23.09.18
23.09.18
16,51 €
06.11.18
06.11.18
-27,37 %
06.11.18
06.11.18